Zevra Therapeutics
ZVRA
40 hedge funds and large institutions have $24.8M invested in Zevra Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 23 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
31% less funds holding
Funds holding: 58 → 40 (-18)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
77% less capital invested
Capital invested by funds: $106M → $24.8M (-$81.4M)
78% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 23
Top Buyers
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.09M |
| 2 |
SIM
Spark Investment Management
New York
|
+$959K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$669K |
| 4 |
DA
DSC Advisors
Chicago,
Illinois
|
+$513K |
| 5 |
Millennium Management
New York
|
+$377K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
51
Boyle Capital Management
West Des Moines,
Iowa
| – | -$420K | -1,810 | Closed |
|
52
UBS Group
Zurich,
Switzerland
| – | -$394K | -1,699 | Closed |
|
53
JP Morgan Chase
New York
| – | -$307K | -1,323 | Closed |
|
|
SCM
54
Segantii Capital Management
Hong Kong
| – | -$241K | -1,006 | Closed |
|
|
ARTA
55
A.R.T. Advisors
New York
| – | -$198K | -854 | Closed |
|
56
Nomura Holdings
Tokyo,
Japan
| – | -$170K | -733 | Closed |
|
|
ICOA
57
Investment Centers of America
Bismarck,
North Dakota
| – | -$152K | -656 | Closed |
|
|
VFS
58
VSR Financial Services
Overland Park,
Kansas
| – | -$150K | -648 | Closed |
|
|
WMSA
59
Weiss Multi-Strategy Advisers
New York
| – | -$145K | -625 | Closed |
|
60
SG Americas Securities
New York
| – | -$140K | -603 | Closed |
|
61
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$99K | -413 | Closed |
|
62
Wells Fargo
San Francisco,
California
| – | -$72K | -309 | Closed |
|
|
TRCT
63
Tower Research Capital (TRC)
New York
| – | -$10K | -43 | Closed |
|
ZVRA Hedge Fund Activity: Q2 2016 in Review
40 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2016, worth a combined $24.8M — down 77% from $106M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ZVRA and 5 opened new positions — a net loss of 18 holders — while 9 trimmed existing stakes and 18 added.
The largest buyer was Alyeska Investment Group, adding an estimated $4.09M. The largest seller was Schroder Investment Management Group, exiting entirely with an estimated $5.14M sold.
- 40 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2016, down from 58 in Q1 2016.
- Funds reported $24.8M of Zevra Therapeutics stock for Q2 2016, down 77% quarter-over-quarter.
- 5 funds opened new Zevra Therapeutics positions in Q2 2016 and 23 closed out, a net change of -18 holders.
- The largest Zevra Therapeutics buyer in Q2 2016 was Alyeska Investment Group, an estimated $4.09M added.
- The largest Zevra Therapeutics seller in Q2 2016 was Schroder Investment Management Group, an estimated $5.14M sold.
Based on aggregated 13F filings for Q2 2016.